ETON

Latest SEC Filings & News for ETON

2 most recent filings and news items mentioning ETON. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/ETON/news?limit=20"

Pull ETON filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

M&AAug 5, 2026Neutral

Eton expands infantile hemangioma franchise with ASN-001 acquisition

Eton Pharmaceuticals licensed the late-stage ASN-001 drug from Auson Pharmaceuticals for treating infantile hemangiomas, projecting significant portfolio revenue growth.

View filing at SEC.gov →

M&AMay 19, 2026Positive

Eton Pharmaceuticals acquires U.S. commercialization rights to IMPAVIDO for leishmaniasis treatment

Eton Pharmaceuticals entered into a supply and distribution agreement to gain exclusive U.S. commercialization rights to IMPAVIDO (miltefosine) from Knight Therapeutics, effective September 26, 2026. The acquisition of this FDA-approved orphan drug expands Eton's rare disease por

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.